Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect
- PMID: 3083889
Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect
Abstract
Highly purified pro-urokinase (pro-UK) or single-chain urokinase-type plasminogen activator (scu-PA) was treated with diisopropylfluorophosphate (1 mmol/L) to eliminate traces of two-chain UK activity. This preparation was found to retain a low activity against a chromogenic substrate (S2444), equivalent to 0.1% to 0.5% of the activity of its plasmin-activated derivative. Evidence is presented that the intrinsic activity of pro-UK (scu-PA) was sufficient to activate plasminogen on a fibrin plate or in buffer and was far more reactive against Lys-plasminogen than against Glu-plasminogen. The relative resistance of Glu-plasminogen to activation was overcome by the addition of lysine (25 mmol/L) to the reaction mixture. By contrast, in plasma, pro-UK (scu-PA) was stable and nonreactive for greater than 72 hours when incubated (37 degrees C). Pro-UK (scu-PA) did not form sodium dodecyl sulfate-stable inhibitor complexes, whereas complexation occurred rapidly with UK. Only at high concentrations of pro-UK (scu-PA) (greater than or equal to 250 IU/mL) did plasminogen activation in plasma occur. The relative inertness of pro-UK (scu-PA) in plasma, in contrast to its low-grade enzymatic activity in buffer, was attributed to the effect of inhibitors. The addition of EDTA or the removal of divalent cations by dialysis was associated with a lower threshold for nonspecific plasminogen activation by pro-UK (scu-PA) in plasma. Replacement of Ca++ but not other cations restored baseline conditions. In the presence of a clot, fibrin-selective plasminogen activation and clot lysis were triggered. Lysis was accompanied by less than 10% conversion of pro-UK (scu-PA) to two-chain UK, suggesting that the intrinsic activity of pro-UK (scu-PA) itself may have been responsible for fibrinolysis, although a contribution by the small amount of UK generated could not be excluded. Similarly, pro-UK (scu-PA) supported clot lysis for several days in the same plasma before the effect dissipated as a result of degradation to UK. When Glu-plasminogen in plasma was replaced by Lys-plasminogen, or when lysine was added to normal plasma, nonselective plasminogen activation and fibrinogenolysis occurred. It was concluded that under the experimental conditions, the fibrin specificity of pro-UK (scu-PA) can be explained by its selective activation of fibrin-bound plasminogen and is due to the latter's Lys-plasminogen-like conformation.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.J Biol Chem. 1993 Sep 5;268(25):18554-9. J Biol Chem. 1993. PMID: 8103046
-
Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.Biochim Biophys Acta. 2001 Apr 7;1546(2):399-405. doi: 10.1016/s0167-4838(01)00161-3. Biochim Biophys Acta. 2001. PMID: 11295444
-
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.Thromb Haemost. 1986 Aug 20;56(1):35-9. Thromb Haemost. 1986. PMID: 3095946
-
Activation of fibrin-bound plasminogen by pro-urokinase and its complementariness with that by tissue plasminogen activator.Enzyme. 1988;40(2-3):97-108. doi: 10.1159/000469151. Enzyme. 1988. PMID: 2971533 Review.
-
Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.J Cell Biochem. 1987 Feb;33(2):77-86. doi: 10.1002/jcb.240330202. J Cell Biochem. 1987. PMID: 3553213 Review.
Cited by
-
Intra-arterial versus intra-venous thrombolysis within and after the first 3 hours of stroke onset.Arch Med Sci. 2010 Jun 30;6(3):303-15. doi: 10.5114/aoms.2010.14248. Arch Med Sci. 2010. PMID: 22371764 Free PMC article.
-
Structural Biology and Protein Engineering of Thrombolytics.Comput Struct Biotechnol J. 2019 Jul 2;17:917-938. doi: 10.1016/j.csbj.2019.06.023. eCollection 2019. Comput Struct Biotechnol J. 2019. PMID: 31360331 Free PMC article. Review.
-
Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement.J Thromb Thrombolysis. 2015 Nov;40(4):480-7. doi: 10.1007/s11239-015-1217-3. J Thromb Thrombolysis. 2015. PMID: 25894475 Free PMC article. Review. No abstract available.
-
Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.J Thromb Haemost. 2023 Apr;21(4):1043-1054. doi: 10.1016/j.jtha.2023.01.008. Epub 2023 Jan 14. J Thromb Haemost. 2023. PMID: 36759279 Free PMC article. Review.
-
Tissue distribution and excretion of 125I-lidamycin in mice and rats.World J Gastroenterol. 2005 Jun 7;11(21):3281-4. doi: 10.3748/wjg.v11.i21.3281. World J Gastroenterol. 2005. PMID: 15929183 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources